{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T03:05:35Z","timestamp":1771902335572,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Tumor necrosis and apoptotic activity are considered important in cancer progression, but these features have not been much studied in melanomas. Our hypothesis was that rapid growth in cutaneous melanomas of the vertical growth phase might lead to tissue hypoxia, alterations in apoptotic activity and tumor necrosis. We proposed that these tumor characteristics might be associated with changes in expression of cell adhesion proteins leading to increased invasive capacity and reduced patient survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A well characterized series of nodular melanoma (originally 202 cases) and other benign and malignant melanocytic tumors (109 cases) were examined for the presence of necrosis, apoptotic activity (TUNEL assay), immunohistochemical expression of hypoxia markers (HIF-1 \u03b1, CAIX, TNF-\u03b1, Apaf-1) and cell adhesion proteins (\u03b1<jats:sub>v<\/jats:sub>\u03b2<jats:sub>3<\/jats:sub> integrin, CD44\/HCAM and osteopontin). We hypothesized that tumor hypoxia and necrosis might be associated with increased invasiveness in melanoma through alterations of tumor cell adhesion proteins.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Necrosis was present in 29% of nodular melanomas and was associated with increased tumor thickness, tumor ulceration, vascular invasion, higher tumor proliferation and apoptotic index, increased expression of \u03b1<jats:sub>v<\/jats:sub>\u03b2<jats:sub>3<\/jats:sub> integrin and poor patient outcome by multivariate analysis. Tumor cell apoptosis did also correlate with reduced patient survival. Expression of TNF-\u03b1 and Apaf-1 was significantly associated with tumor thickness, and osteopontin expression correlated with increased tumor cell proliferation (Ki-67).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Tumor necrosis and apoptotic activity are important features of melanoma progression and prognosis, at least partly through alterations in cell adhesion molecules such as increased \u03b1<jats:sub>v<\/jats:sub>\u03b2<jats:sub>3<\/jats:sub> integrin expression, revealing potentially important targets for new therapeutic approaches to be further explored.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-8-362","type":"journal-article","created":{"date-parts":[[2008,12,5]],"date-time":"2008-12-05T19:13:47Z","timestamp":1228504427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Tumor necrosis is associated with increased alphavbeta3integrin expression and poor prognosis in nodular cutaneous melanomas"],"prefix":"10.1186","volume":"8","author":[{"given":"Ingeborg M","family":"Bachmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita G","family":"Ladstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oddbj\u00f8rn","family":"Straume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George N","family":"Naumov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars A","family":"Akslen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,5]]},"reference":[{"key":"1300_CR1","first-page":"1845","volume":"6","author":"O Straume","year":"2000","unstructured":"Straume O, Sviland L, Akslen LA: Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res. 2000, 6: 1845-1853.","journal-title":"Clin Cancer Res"},{"key":"1300_CR2","doi-asserted-by":"publisher","first-page":"8606","DOI":"10.1158\/1078-0432.CCR-05-0011","volume":"11","author":"IM Bachmann","year":"2005","unstructured":"Bachmann IM, Straume O, Puntervoll HE, Kalvenes MB, Akslen LA: Importance of P-cadherin, beta-catenin, and Wnt5a\/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma. Clin Cancer Res. 2005, 11: 8606-8614.","journal-title":"Clin Cancer Res"},{"issue":"Pt 9","key":"1300_CR3","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1242\/jcs.113.9.1535","volume":"113","author":"M Hsu","year":"2000","unstructured":"Hsu M, Andl T, Li G, Meinkoth JL, Herlyn M: Cadherin repertoire determines partner-specific gap junctional communication during melanoma progression. J Cell Sci. 2000, 113 (Pt 9): 1535-1542.","journal-title":"J Cell Sci"},{"key":"1300_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0002-9440(10)64554-3","volume":"157","author":"KL Talks","year":"2000","unstructured":"Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000, 157: 411-421.","journal-title":"Am J Pathol"},{"key":"1300_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/ijc.20984","volume":"116","author":"JP Dales","year":"2005","unstructured":"Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, Allasia C, Bonnier P, Charpin C: Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer. 2005, 116: 734-739.","journal-title":"Int J Cancer"},{"key":"1300_CR6","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1158\/1078-0432.CCR-04-1685","volume":"11","author":"K Nakanishi","year":"2005","unstructured":"Nakanishi K, Hiroi S, Tominaga S, Aida S, Kasamatsu H, Matsuyama S, Matsuyama T, Kawai T: Expression of hypoxia-inducible factor-1alpha protein predicts survival in patients with transitional cell carcinoma of the upper urinary tract. Clin Cancer Res. 2005, 11: 2583-2590.","journal-title":"Clin Cancer Res"},{"key":"1300_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ijc.20052","volume":"111","author":"DE Swinson","year":"2004","unstructured":"Swinson DE, Jones JL, Cox G, Richardson D, Harris AL, O'Byrne KJ: Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer. 2004, 111: 43-50.","journal-title":"Int J Cancer"},{"key":"1300_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4161\/cc.3.2.618","volume":"3","author":"C Potter","year":"2004","unstructured":"Potter C, Harris AL: Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle. 2004, 3: 164-167.","journal-title":"Cell Cycle"},{"key":"1300_CR9","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.2001.19.16.3660","volume":"19","author":"SK Chia","year":"2001","unstructured":"Chia SK, Wykoff CC, Watson PH, Han C, Leek RD, Pastorek J, Gatter KC, Ratcliffe P, Harris AL: Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001, 19: 3660-3668.","journal-title":"J Clin Oncol"},{"key":"1300_CR10","first-page":"7992","volume":"61","author":"A Giatromanolaki","year":"2001","unstructured":"Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL: Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001, 61: 7992-7998.","journal-title":"Cancer Res"},{"key":"1300_CR11","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0002-9440(10)64038-2","volume":"158","author":"S Ivanov","year":"2001","unstructured":"Ivanov S, Liao SY, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, Zavada J, Waheed A, Sly W, Lerman MI, Stanbridge EJ: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001, 158: 905-919.","journal-title":"Am J Pathol"},{"key":"1300_CR12","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0002-9440(10)64779-7","volume":"157","author":"JC Reed","year":"2000","unstructured":"Reed JC: Mechanisms of apoptosis. Am J Pathol. 2000, 157: 1415-1430.","journal-title":"Am J Pathol"},{"key":"1300_CR13","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bjc.6602092","volume":"91","author":"DL Dai","year":"2004","unstructured":"Dai DL, Martinka M, Bush JA, Li G: Reduced Apaf-1 expression in human cutaneous melanomas. Br J Cancer. 2004, 91: 1089-1095.","journal-title":"Br J Cancer"},{"key":"1300_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-0749.2005.00280.x","volume":"19","author":"K Niedojadlo","year":"2006","unstructured":"Niedojadlo K, Labedzka K, Lada E, Milewska A, Chwirot BW: Apaf-1 expression in human cutaneous melanoma progression and in pigmented nevi. Pigment Cell Res. 2006, 19: 43-50.","journal-title":"Pigment Cell Res"},{"key":"1300_CR15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/j.1600-0625.2005.00360.x","volume":"14","author":"M Campioni","year":"2005","unstructured":"Campioni M, Santini D, Tonini G, Murace R, Dragonetti E, Spugnini EP, Baldi A: Role of Apaf-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol. 2005, 14: 811-818.","journal-title":"Exp Dermatol"},{"key":"1300_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4161\/cbt.1.5.158","volume":"1","author":"EC McGary","year":"2002","unstructured":"McGary EC, Lev DC, Bar-Eli M: Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther. 2002, 1: 459-465.","journal-title":"Cancer Biol Ther"},{"key":"1300_CR17","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1091\/mbc.E04-12-1082","volume":"16","author":"KD Cowden Dahl","year":"2005","unstructured":"Cowden Dahl KD, Robertson SE, Weaver VM, Simon MC: Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. Mol Biol Cell. 2005, 16: 1901-1912.","journal-title":"Mol Biol Cell"},{"key":"1300_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1006\/jsre.1996.0242","volume":"63","author":"TJ Hieken","year":"1996","unstructured":"Hieken TJ, Farolan M, Ronan SG, Shilkaitis A, Wild L, Das Gupta TK: Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res. 1996, 63: 169-173.","journal-title":"J Surg Res"},{"key":"1300_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/ijc.10521","volume":"101","author":"M Trikha","year":"2002","unstructured":"Trikha M, Timar J, Zacharek A, Nemeth JA, Cai Y, Dome B, Somlai B, Raso E, Ladanyi A, Honn KV: Role for beta3 integrins in human melanoma growth and survival. Int J Cancer. 2002, 101: 156-167.","journal-title":"Int J Cancer"},{"key":"1300_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0065-2776(08)60537-4","volume":"54","author":"J Lesley","year":"1993","unstructured":"Lesley J, Hyman R, Kincade PW: CD44 and its interaction with extracellular matrix. Adv Immunol. 1993, 54: 271-335.","journal-title":"Adv Immunol"},{"key":"1300_CR21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0959-8049(96)00512-6","volume":"33","author":"A Dietrich","year":"1997","unstructured":"Dietrich A, Tanczos E, Vanscheidt W, Schopf E, Simon JC: High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer. 1997, 33: 926-930.","journal-title":"Eur J Cancer"},{"key":"1300_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-2303.2002.00376.x","volume":"13","author":"V Sviatoha","year":"2002","unstructured":"Sviatoha V, Rundgren A, Tani E, Hansson J, Kleina R, Skoog L: Expression of CD40, CD44, bcl-2 antigens and rate of cell proliferation on fine needle aspirates from metastatic melanoma. Cytopathology. 2002, 13: 11-21.","journal-title":"Cytopathology"},{"key":"1300_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1600-0560.1998.tb01719.x","volume":"25","author":"H Schaider","year":"1998","unstructured":"Schaider H, Soyer HP, Heider KH, Hofmann-Wellenhof R, Zatloukal K, Smolle J, Kerl H: CD44 and variants in melanocytic skin neoplasms. J Cutan Pathol. 1998, 25: 199-203.","journal-title":"J Cutan Pathol"},{"key":"1300_CR24","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0002-9440(10)64608-1","volume":"157","author":"JM Karjalainen","year":"2000","unstructured":"Karjalainen JM, Tammi RH, Tammi MI, Eskelinen MJ, Agren UM, Parkkinen JJ, Alhava EM, Kosma VM: Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol. 2000, 157: 957-965.","journal-title":"Am J Pathol"},{"key":"1300_CR25","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1046\/j.1365-2133.1998.02255.x","volume":"138","author":"T Ichikawa","year":"1998","unstructured":"Ichikawa T, Masumoto J, Kaneko M, Saida T, Sagara J, Taniguchi S: Moesin and CD44 expression in cutaneous melanocytic tumours. Br J Dermatol. 1998, 138: 763-768.","journal-title":"Br J Dermatol"},{"key":"1300_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1080\/03008200290001050","volume":"43","author":"J Sodek","year":"2002","unstructured":"Sodek J, Zhu B, Huynh MH, Brown TJ, Ringuette M: Novel functions of the matricellular proteins osteopontin and osteonectin\/SPARC. Connect Tissue Res. 2002, 43: 308-319.","journal-title":"Connect Tissue Res"},{"key":"1300_CR27","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1359\/jbmr.2004.19.10.1706","volume":"19","author":"Y Ohyama","year":"2004","unstructured":"Ohyama Y, Nemoto H, Rittling S, Tsuji K, Amagasa T, Denhardt DT, Nifuji A, Noda M: Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures. J Bone Miner Res. 2004, 19: 1706-1711.","journal-title":"J Bone Miner Res"},{"key":"1300_CR28","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/j.0022-202X.2005.23680.x","volume":"124","author":"Y Zhou","year":"2005","unstructured":"Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G: Osteopontin expression correlates with melanoma invasion. J Invest Dermatol. 2005, 124: 1044-1052.","journal-title":"J Invest Dermatol"},{"key":"1300_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/cncr.23147","volume":"112","author":"J Rangel","year":"2008","unstructured":"Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR, Sagebiel RW, Kashani-Sabet M: Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008, 112: 144-150.","journal-title":"Cancer"},{"key":"1300_CR30","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","volume":"172","author":"A Breslow","year":"1970","unstructured":"Breslow A: Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970, 172: 902-908.","journal-title":"Ann Surg"},{"key":"1300_CR31","first-page":"705","volume":"29","author":"WH Clark Jr","year":"1969","unstructured":"Clark WH, From L, Bernardino EA, Mihm MC: The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969, 29: 705-727.","journal-title":"Cancer Res"},{"key":"1300_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0002-9440(10)61688-4","volume":"159","author":"O Straume","year":"2001","unstructured":"Straume O, Akslen LA: Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol. 2001, 159: 223-235.","journal-title":"Am J Pathol"},{"key":"1300_CR33","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1038\/nm0798-844","volume":"4","author":"J Kononen","year":"1998","unstructured":"Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4: 844-847.","journal-title":"Nat Med"},{"key":"1300_CR34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0002-9440(10)64922-X","volume":"160","author":"O Straume","year":"2002","unstructured":"Straume O, Akslen LA: Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor\/fibroblast growth factor receptor-1 and ephrin-A1\/EphA2 on melanoma progression. Am J Pathol. 2002, 160: 1009-1019.","journal-title":"Am J Pathol"},{"key":"1300_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D","volume":"194","author":"A Nocito","year":"2001","unstructured":"Nocito A, Bubendorf L, Maria Tinner E, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knonagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jager P, Luc Fehr J, Schraml P, Moch H, Mihatsch MJ, Gasser T, Sauter G: Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol. 2001, 194: 349-357.","journal-title":"J Pathol"},{"key":"1300_CR36","first-page":"595","volume":"15","author":"O Straume","year":"1999","unstructured":"Straume O, Salvesen HB, Akslen LA: Angiogenesis is prognostically important in vertical growth phase melanomas. Int J Oncol. 1999, 15: 595-599.","journal-title":"Int J Oncol"},{"key":"1300_CR37","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0360-3016(02)02815-8","volume":"53","author":"HK Haugland","year":"2002","unstructured":"Haugland HK, Vukovic V, Pintilie M, Fyles AW, Milosevic M, Hill RP, Hedley DW: Expression of hypoxia-inducible factor-1alpha in cervical carcinomas: correlation with tumor oxygenation. Int J Radiat Oncol Biol Phys. 2002, 53: 854-861.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1300_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<535::AID-IJC10>3.0.CO;2-5","volume":"74","author":"O Straume","year":"1997","unstructured":"Straume O, Akslen LA: Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer. 1997, 74: 535-539.","journal-title":"Int J Cancer"},{"key":"1300_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","volume":"26","author":"P Vaupel","year":"2007","unstructured":"Vaupel P, Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26: 225-239.","journal-title":"Cancer Metastasis Rev"},{"key":"1300_CR40","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1158\/0008-5472.CAN-04-3039","volume":"65","author":"EK Rofstad","year":"2005","unstructured":"Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K: The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res. 2005, 65: 2387-2396.","journal-title":"Cancer Res"},{"key":"1300_CR41","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/S0002-9440(10)65730-6","volume":"153","author":"MY Hsu","year":"1998","unstructured":"Hsu MY, Shih DT, Meier FE, van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M: Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol. 1998, 153: 1435-1442.","journal-title":"Am J Pathol"},{"key":"1300_CR42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/S0046-8177(99)90202-2","volume":"30","author":"PA van Belle","year":"1999","unstructured":"van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry Dt, Schuchter L, van Belle TJ, Albelda S, Tahin P, Herlyn M, Elder DE: Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol. 1999, 30: 562-567.","journal-title":"Hum Pathol"},{"key":"1300_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijc.20377","volume":"112","author":"P Koistinen","year":"2004","unstructured":"Koistinen P, Ahonen M, Kahari VM, Heino J: alphaV integrin promotes in vitro and in vivo survival of cells in metastatic melanoma. Int J Cancer. 2004, 112: 61-70.","journal-title":"Int J Cancer"},{"key":"1300_CR44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00008390-200402000-00005","volume":"14","author":"J Nikkola","year":"2004","unstructured":"Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J, Pyrhonen S: Integrin chains beta1 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res. 2004, 14: 29-37.","journal-title":"Melanoma Res"},{"key":"1300_CR45","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1078\/0171-9335-00067","volume":"79","author":"S Castel","year":"2000","unstructured":"Castel S, Pagan R, Garcia R, Casaroli-Marano RP, Reina M, Mitjans F, Piulats J, Vilaro S: Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells. Eur J Cell Biol. 2000, 79: 502-512.","journal-title":"Eur J Cell Biol"},{"key":"1300_CR46","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/1097-0215(20000901)87:5<716::AID-IJC14>3.0.CO;2-R","volume":"87","author":"F Mitjans","year":"2000","unstructured":"Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J: In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer. 2000, 87: 716-723.","journal-title":"Int J Cancer"},{"key":"1300_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.0906-6705.2004.00136.x","volume":"13","author":"A Baldi","year":"2004","unstructured":"Baldi A, Santini D, Russo P, Catricala C, Amantea A, Picardo M, Tatangelo F, Botti G, Dragonetti E, Murace R, Tonini G, Natali PG, Baldi F, Paggi MG: Analysis of APAF-1 expression in human cutaneous melanoma progression. Exp Dermatol. 2004, 13: 93-97.","journal-title":"Exp Dermatol"},{"key":"1300_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/jcp.48.3.242","volume":"48","author":"EE Mooney","year":"1995","unstructured":"Mooney EE, Ruis Peris JM, O'Neill A, Sweeney EC: Apoptotic and mitotic indices in malignant melanoma and basal cell carcinoma. J Clin Pathol. 1995, 48: 242-244.","journal-title":"J Clin Pathol"},{"key":"1300_CR49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/modpathol.3880535","volume":"15","author":"T Shukuwa","year":"2002","unstructured":"Shukuwa T, Katayama I, Koji T: Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. Mod Pathol. 2002, 15: 387-396.","journal-title":"Mod Pathol"},{"key":"1300_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S1535-6108(02)00241-6","volume":"3","author":"JC Reed","year":"2003","unstructured":"Reed JC: Apoptosis-targeted therapies for cancer. Cancer Cell. 2003, 3: 17-22.","journal-title":"Cancer Cell"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-8-362\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-362","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-362.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:45:07Z","timestamp":1630464307000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-8-362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["1300"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-8-362","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"3 July 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"362"}}